AXIOS July 9, 2024
Two of the buzziest technology trends in health care — artificial intelligence and weight-loss drugs — appear to be converging as companies increasingly scope out the potential to capitalize on both.
Why it matters: Some companies tell Axios the explosive demand, outsized costs and wide range of potential of uses for GLP-1s — the category of drugs that includes diabetes drug Ozempic and its weight-loss counterpart Wegovy — make them the perfect test case for AI’s potential.
“With any hot space, there’s always a lot of noise. It’s unavoidable,” said Alexander Singh, founder of Alfie Health, an AI obesity care startup that was recently acquired by obesity care platform Knownwell.
- He’s among those who argue there’s some true value...
Today's Sponsors
Today's Sponsor